ERIS LIFESCIENCES share price has zoomed 4% and is presently trading at Rs 1,345.0.
Meanwhile, the BSE HEALTHCARE index is at 42,193.7 (up 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are Biocon (up 2.9%) and GSK Pharma (up 2.0%).
GLAND PHARMA (down 1.8%) and DR. LAL PATHLABS (down 1.6%) are among the top losers today.
Over the last one year, ERIS LIFESCIENCES has moved up from Rs 897.4 to Rs 1,345.0, registering a gain of Rs 447.7 (up 49.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,951.5 to 42,193.7, registering a gain of 45.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 177.8%), SUVEN PHARMACEUTICALS (up 124.6%) and Glenmark Pharma (up 100.5%).
The BSE Sensex is at 77,548.0 (up 0.3%).
The top gainers among the BSE Sensex today are Nestle (up 2.0%) and Tech Mahindra (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 23,590.1 (up 0.6%). NTPC and Trent are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,675.9 to 77,548.0, registering a gain of 11,872.1 points (up 18.1%).
ERIS LIFESCIENCES net profit fell 21.2% YoY to Rs 964 million for the quarter ended September 2024, compared to a profit of Rs 1,223 million a year ago. Net sales rose 46.7% to Rs 7,412 million during the period as against Rs 5,053 million in July-September 2023.
For the year ended March 2024, ERIS LIFESCIENCES reported 6.1% increase in net profit to Rs 3,971 million compared to net profit of Rs 3,742 million during FY23. Revenue of the company grew 19.2% to Rs 20,091 million during FY24.
The current Price to earnings ratio of ERIS LIFESCIENCES, based on rolling 12 month earnings, stands at 49.9.
Equitymaster requests your view! Post a comment on "ERIS LIFESCIENCES Gains 4%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!